I-MAB/$IMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Ticker
$IMAB
Sector
Primary listing
Employees
32
Headquarters
Website
I-MAB Metrics
BasicAdvanced
$470M
-
-$0.45
1.37
-
Price and volume
Market cap
$470M
Beta
1.37
52-week high
$5.90
52-week low
$0.60
Average daily volume
3.8M
Financial strength
Current ratio
22.817
Quick ratio
22.542
Long term debt to equity
1.336
Total debt to equity
1.769
Profitability
EBITDA (TTM)
-38.009
Management effectiveness
Return on assets (TTM)
-10.36%
Return on equity (TTM)
-17.08%
Valuation
Price to book
1.7
Price to tangible book (TTM)
1.7
Growth
Earnings per share change (TTM)
-66.72%
3-year earnings per share growth (CAGR)
-51.60%
What the Analysts think about I-MAB
Analyst ratings (Buy, Hold, Sell) for I-MAB stock.
Bulls say / Bears say
I-Mab has a solid financial footing, holding $173.4 million in cash, cash equivalents, and short-term investments as of December 31, 2024, which is enough to fund planned clinical milestones and operations through 2027 (GlobeNewswire)
Enrollment for the Phase 1b givastomig combination study finished ahead of schedule in the first dose expansion group, and the first patient has already been dosed in the second, showing speedy trial progress and strong engagement from investigators (GlobeNewswire)
At ESMO GI 2025, positive Phase 1b dose escalation data showed a 71% objective response rate across all doses and 83% at expansion doses, with responses seen even in tumors with low PD-L1 or CLDN18.2 expression, and the treatment was well tolerated (NASDAQ)
Givastomig’s Phase 1b results, though strong, are based on just 17 patients in dose-escalation groups and do not include long-term efficacy or survival data, so any clinical benefit remains unproven until larger cohort results are available in early 2026 (GlobeNewswire)
Ragistomig is still in early Phase 1 testing and, since its composition-of-matter patent was issued in October 2024, has not shown any efficacy results, leaving its short-term commercial prospects and development schedule highly uncertain (GlobeNewswire)
I-Mab is entering a prolonged period without significant clinical news, as top-line uliledlimab/chemotherapy study results are not expected until the second half of 2025 and givastomig expansion cohort data are likely in the first half of 2026, potentially keeping shares muted in the meantime (TradingView/Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
I-MAB Financial Performance
Revenues and expenses
I-MAB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for I-MAB stock?
I-MAB (IMAB) has a market cap of $470M as of September 15, 2025.
What is the P/E ratio for I-MAB stock?
The price to earnings (P/E) ratio for I-MAB (IMAB) stock is 0 as of September 15, 2025.
Does I-MAB stock pay dividends?
No, I-MAB (IMAB) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next I-MAB dividend payment date?
I-MAB (IMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for I-MAB?
I-MAB (IMAB) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.